导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.91% | 1717/4766 |
| 近一周 | -1.59% | 2335/5456 |
| 近一月 | -2.98% | 2057/5412 |
| 近一季 | -5.47% | 2073/5222 |
| 近半年 | 1.26% | 1184/4911 |
| 近一年 | 4.95% | 1774/4391 |
| 近两年 | 47.80% | 1572/2953 |
| 近三年 | 33.00% | 970/2252 |
| 成立以来 | 8.76% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.59% 2830/4961 |
15.52% 1662/5312 |
- - |
- - |
| 2025 | 20.39% 2124/4813 |
-0.40% 2230/3635 |
2.27% 1693/4076 |
18.90% 2230/4524 |
-0.60% 2564/4813 |
| 2024 | 14.35% 1054/3463 |
4.49% 452/2808 |
0.03% 654/3014 |
13.10% 2245/3129 |
-3.27% 2309/3463 |
| 2023 | -7.52% 924/2656 |
3.31% 1393/3759 |
-2.46% 1302/3909 |
-2.73% 727/4055 |
-5.64% 2376/4209 |
| 2022 | -21.99% 1448/3578 |
-13.88% 667/2804 |
5.85% 1843/3205 |
-13.20% 1902/3430 |
-1.42% 1830/3570 |
| 2021 | 1.38% 926/2717 |
-2.41% 678/1745 |
7.42% 1187/2232 |
-2.37% 901/2560 |
-0.94% 1697/2708 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中银沪深300指数增强C VS. 长安沪深300非周期A(740101) |